Jivi (damoctocog alfa pegol)
- Region
- 🇪🇺 EU
- Active substance
- damoctocog alfa pegol
- Company
- Bayer AG
- Status
- Authorised
- Therapeutic area
- Hemophilia A
- CHMP opinion
- Thu 20 Sep 2018
- EU approval
- Thu 22 Nov 2018
- Application
- EMEA/H/C/004054
- ATC
- B02BD02
- Official record
- www.ema.europa.eu
Indication
Treatment and prophylaxis of bleeding in previously treated patients (PTPs) ≥ 7 years of age with haemophilia A (congenital factor VIII deficiency).
Regulatory milestones
No milestones recorded in the last year.
Follow Jivi
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.